- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00921336
Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor
Open-Label, Sequential, Ascending, Multi-Dose, Phase 1 Study of KW-2450 as Monotherapy in Subjects With Previously Treated Advanced Solid Tumor
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
This open-label, sequential, ascending, multi-dose, Phase 1 study will enroll up to 72 subjects with previously treated advanced solid tumor. Subjects at each dose level will receive KW-2450 orally, once daily for 28 days followed by a 1-week observation period. After completing the 1 week observation period, all subjects will receive KW-2450 on a continuous daily schedule. All doses of KW-2450 will be administered to subjects under overnight fasting conditions.
Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated titration. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached.
Opintotyyppi
Ilmoittautuminen (Odotettu)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21201-1595
- University of Maryland Greenbaum Cancer Center
-
-
Michigan
-
Detroit, Michigan, Yhdysvallat, 48201
- Karmanos Cancer Institute
-
-
New York
-
New York, New York, Yhdysvallat, 10021
- Memorial Sloan Kettering
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Voluntary signed and dated Institutional Review Board (IRB) approved informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with regulatory and institutional guidelines. This must be obtained before performing protocol-related procedures that are not part of standard subject care
- Histopathologically- or cytologically-documented, advanced primary or recurrent solid tumor that has not responded to an adequate course of available therapy, that has progressed or recurred despite an adequate course of available therapy, that is not curable by available therapy or for which no accepted standard therapy exists
- Ability to comply with visits/procedures required by the protocol. Subjects enrolled in this trial must be treated at a participating center
- A life expectancy of >3 months
- Eastern Cooperative Oncology Group (ECOG) performance status score of <= 2 at study entry
Adequate hematologic function, as defined by:
an absolute neutrophil count (ANC) >= 1500/mm3 a hemoglobin level >=8.5 gm/dL a platelet count >=100,000/mm3
Adequate hepatic function, as defined by:
a total bilirubin level <= 1.5 x the upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine transaminase (ALT) levels <= 2.5 x the ULN or <= 5 x the ULN if known liver metastases
Adequate renal function, as defined by:
a serum creatinine (Scr) <= 1.5 mg/dL for male subjects; Scr <= 1.40 mg/dL for female subjects Calculated creatine clearance > 60 mL/min based on Cockcroft-Gault formula
- Subjects must be recovered from the effects of any prior anti-neoplastic therapy. The ongoing adverse events due to these therapies must be <=Grade 1 prior to entering the study. At least 5 half-lives should have elapsed for any investigational agents prior to the administration of study medication
- Subjects with central nervous system (CNS) metastases are eligible for enrollment if they have received prior radiotherapy and/or surgery to site(s) of CNS metastatic disease, have been off glucocorticoids for at least 4 weeks, are not taking anticonvulsants, and have no overt evidence of neurological deficit
- Men and women, >= 18 years of age at the time of enrollment
Women of childbearing potential (WOCBP) must agree to use effective contraception, defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm) or abstain from sexual intercourse during the study and for 90 days following the last dose of KW-2450.
WOCBP include females who have experienced menarche and who have not undergone successful sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal (defined as amenorrhea >= 12 consecutive months)
- Male subjects must be willing to use an appropriate method of contraception (e.g., condoms) or abstain from sexual intercourse and inform any sexual partners that they must also use a reliable method of contraception (e.g., birth control pills) during the study and for 90 days following the last dose of KW-2450
- WOCBP must have a negative pregnancy test within 7 days of receiving study medication.
Exclusion Criteria:
- Women who are pregnant or lactating
Known diabetes defined as:
- random serum glucose concentration of > 200 mg/dL
- fasting plasma glucose (FPG) of > 126 mg/dL
- 2-hour post load serum glucose concentration of > 200 mg/dL following an oral glucose tolerance test
- the need for an oral hypoglycemic agent or insulin in order to keep the serum glucose below the above levels; or
- any diabetic complication (cataract, retinopathy, nephropathy, etc.).
- Subjects showing clinical evidence or with a history of cataract(s) or retinopathy
- Abnormal free T4 values. Abnormal thyroid stimulating hormone (TSH) values at enrollment will be further evaluated by free T4. Subjects with abnormal free T4 values and a history or evidence of thyroid disease will be excluded.
- Subjects who are unable or unwilling to take metformin
Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection requiring parenteral antibiotics;
- A serious or nonhealing active wound, ulcer, or bone fracture;
- Uncontrolled hypertension (systolic blood pressure >160 mm Hg, diastolic blood pressure >100 mm Hg, found on two consecutive measurements separated by a 1week period despite treatment with two antihypertensive agents)
- Unstable cardiovascular disease (i.e., including uncontrolled ischemic heart disease, congestive heart failure, arrhythmia or hypertension; New York Heart Association >= class III; or myocardial infarction or acute coronary syndrome within 6 months)
- Positive for human immunodeficiency virus, hepatitis B or C
- Subjects with inflammatory diseases of the gastrointestinal tract or malabsorption syndrome
- Major surgery within 4 weeks prior to the administration of study medication
- Evidence of organ dysfunction or any clinically significant deviation in physical examination, vital signs, or clinical laboratory determination;
- Prolonged QT intervals or any clinically significant abnormalities on ECG
- A history of prior treatment with other agents specifically targeting IGFRs
- Subjects who require pharmacological doses of glucocorticoids beyond replacement doses. The use of topical, intra-ocular or inhalation glucocorticoids is permitted
- Strong inhibitors/inducers of CYP3A4/5, herbal medications (within 1 week of administration of study medication), or drugs for prevention of graft versus host disease or transplant rejection (within 2 months prior to the administration of study medication)
- Hematopoetic growth factors and erythropoiesis-stimulating agents within 3 weeks prior to the administration of study medication
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: KW-2450
|
Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose.
The safety of each dose level will be established prior to enrollment of subjects in the next dose level.
Dose escalation will proceed sequentially with accelerated escalation.
Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule.
Up to 6 subjects will be enrolled at each dose level.
Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached.
The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
---|---|
To establish the safety, tolerability, and recommended Phase 2 dose of KW 2450 administered orally in subjects with advanced solid tumor who have not responded to standard therapy or for whom no standard therapy is available
Aikaikkuna: 28 days
|
28 days
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
---|---|
To determine the PK/PD profile of KW-2450
Aikaikkuna: PK/PD perfomed up to Day 29 Tumor assessments performed at 8 weeks
|
PK/PD perfomed up to Day 29 Tumor assessments performed at 8 weeks
|
To evaluate for preliminary evidence of efficacy
Aikaikkuna: PK/PD perfomed up to Day 29 Tumor assessments performed at 8 weeks
|
PK/PD perfomed up to Day 29 Tumor assessments performed at 8 weeks
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2450-US-001
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Kiinteä kasvain
-
Samsung Medical CenterMinistry of Health, Republic of KoreaEi vielä rekrytointiaUusiutunut lasten kiinteä kasvain | Refractory Pediatric Solid TumorKorean tasavalta
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRekrytointiUusiutunut lasten AML | Tulenkestävä lasten AML | Uusiutunut lasten kiinteä kasvain | Refractory Pediatric Solid TumorKorean tasavalta
-
Millennium Pharmaceuticals, Inc.Valmis
-
Novartis PharmaceuticalsValmiscMET-dysregulated Advanced Solid TumorsYhdysvallat, Espanja, Italia, Bulgaria, Yhdistynyt kuningaskunta, Ranska, Tanska
-
Novartis PharmaceuticalsValmiscMET Dysegulation Advanced Solid TumorsItävalta, Tanska, Ruotsi, Yhdistynyt kuningaskunta, Espanja, Saksa, Alankomaat, Yhdysvallat
-
Shanghai Pudong HospitalUTC Therapeutics Inc.PeruutettuMesoteliinipositiiviset Advanced Refractory Solid TumorsKiina
-
Novartis PharmaceuticalsValmiscMET-dysregulated Advanced Solid TumorsYhdysvallat, Italia, Espanja, Yhdistynyt kuningaskunta, Kreikka, Belgia, Itävalta, Tšekki
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRekrytointiKRAS G12C Mutant Advanced Solid TumorsKiina
-
AmgenAktiivinen, ei rekrytointiKRAS p.G12C Mutant Advanced Solid TumorsYhdysvallat, Ranska, Kanada, Espanja, Belgia, Korean tasavalta, Itävalta, Australia, Unkari, Kreikka, Saksa, Japani, Romania, Sveitsi, Brasilia, Portugali
Kliiniset tutkimukset KW-2450
-
LivaNovaValmisSinussolmun toimintahäiriö | Bradykardia-takykardia-oireyhtymä | Paroksismaalinen atrioventrikulaarinen salpausYhdistynyt kuningaskunta, Ranska, Saksa, Belgia, Italia
-
Kyowa Kirin Co., Ltd.Valmis
-
Kyowa Kirin, Inc.ValmisMaksan vajaatoimintaYhdysvallat
-
Kyowa Kirin, Inc.ValmisTerveet mieskohteetYhdysvallat
-
Kyowa Hakko Kirin Pharma, Inc.LopetettuAkuutti myelooinen leukemia (AML)Yhdysvallat
-
Kyowa Kirin Co., Ltd.LopetettuDisseminoitu intravaskulaarinen koagulaatio (DIC)Japani
-
Kyowa Kirin Co., Ltd.ValmisDisseminoitu intravaskulaarinen koagulaatio (DIC)Japani
-
Kyowa Kirin, Inc.LopetettuMyelodysplastiset oireyhtymät | Akuutti lymfoblastinen leukemia | Akuutti myelooinen leukemia | Krooninen myelooinen leukemiaYhdysvallat
-
Kyowa Kirin Co., Ltd.Valmis
-
Pennington Biomedical Research CenterPeruutettu